Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Precipio, Inc. filings document the public-company disclosures of a specialty cancer diagnostics issuer with Pathology Services and Products operations. Its Form 8-K reports include Regulation FD updates for shareholder calls and investor presentations, furnished financial results, and material-event disclosures related to corporate communications and operating performance.
The company’s proxy materials describe annual meeting procedures, stockholder voting matters, governance, and access to annual reporting materials. Other filings document capital-structure matters, including common stock activity and the termination of an at-the-market sales agreement, alongside formal exhibits and disclosures tied to Precipio’s diagnostics business and shareholder communications.
Precipio, Inc. reported second-quarter 2026 results, highlighting a record quarterly revenue level surpassing $7M as customer growth continued. Management also noted that product revenues increased 21% from the previous high of $0.75M in Q4 2025 and that cash rose to over $3M, achieved without a financing event.
On profitability, the company posted a Q2 2026 net loss of $0.2M compared with net income of $0.1M in Q2 2025. EBITDA was approximately $0.0M versus $0.4M a year earlier, while Adjusted EBITDA turned positive at $0.4M compared with $(0.1)M in Q2 2025, reflecting add-backs including $0.8M of stock-based compensation and $(0.4)M of other significant income. The company positions Adjusted EBITDA as a key non-GAAP measure of operating performance.
Precipio plans a shareholder call on August 17, 2026 at 5 PM ET to provide additional discussion of the quarter, including commentary on its cancer diagnostics business and a moderated Q&A session.
Precipio, Inc. reported higher net sales and case volumes for the quarter and six months ended June 30, 2026, but remains unprofitable and subject to substantial doubt about its ability to continue as a going concern. Net sales for the quarter rose to $7.0 million, up 24% year over year, driven by a 26% increase in diagnostic cases to 4,652 and stronger product revenue. For the first half of 2026, net sales were $13.7 million, up 30%, with cases up 42% to 9,564.
Gross profit improved to $3.1 million for the quarter and $5.9 million year to date, with gross margins of 45% and 43%, respectively. Operating expenses increased, including a $0.9 million rise in stock-based compensation over six months, leading to an operating loss of $2.0 million and a net loss of $1.7 million for the first half. Operating cash flow was positive at $0.7 million, supported by $0.4 million of non-recurring Employee Retention Credit receipts. As of June 30, 2026, the company held $3.1 million in cash, working capital of $2.8 million, total assets of $21.3 million, and an accumulated deficit of $104.5 million. Management states that continued operations over the next twelve months depend on executing the business plan, generating additional revenue, and obtaining financing as needed, and explicitly notes substantial doubt about the company’s ability to continue as a going concern.
Precipio, Inc. announced it will host a Q2‑2026 shareholder update call on August 17, 2026 at 5:00 PM ET. The specialty cancer diagnostics company plans to provide remarks on its current core businesses and include a dedicated moderated live Q&A session.
CEO Ilan Danieli stated that the team is making progress in adding customers, expanding the pipeline, and growing the business, and that this will be reflected in upcoming Q2 results. Investors can participate via conference line 646.307.1865, with a replay available through the company’s investor relations website.
Valauri Christina Rizopoulos reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Christina Rizopoulos received an equity compensation award of 108 shares of common stock on July 15, 2026. The shares were granted at a value of $25.24 per share as consideration in lieu of cash payment for her Board service for Q2-26.
Following this award, she holds 5,628 Precipio common shares directly.
Cossman Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director Jeffrey Cossman received a grant of 416 shares of common stock on July 15, 2026, as equity compensation in lieu of cash fees for Q2-26 Board of Directors service.
After this award, he holds 16,549 common shares directly.
Cohen David Seth reported acquisition or exercise transactions in this Form 4 filing.
Precipio, Inc. director David Seth Cohen received a grant of 520 shares of common stock on July 15, 2026, as compensation for Q2-26 board service, taken in stock in lieu of cash. The award, valued at $25.24 per share, increased his directly held position to 55,199 shares.
Precipio, Inc. reported the results of its Annual Meeting of stockholders. Holders of 1,063,293 common shares, or 59.57% of the 1,784,830 shares entitled to vote, were present in person or by proxy, so a quorum was reached.
Stockholders elected Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D. as Class II directors with terms expiring in 2029. They also ratified the appointment of CBIZ CPAs, P.C. as the company’s independent registered public accounting firm for the year ending December 31, 2026. No other matters were brought to a vote.
Precipio, Inc. director Richard A. Sandberg reported an indirect open-market sale related to shares of the company’s common stock. On May 21, 2026, Wythburn Associates, Ltd., an entity 94% owned jointly by Sandberg and his spouse, sold 900 shares at an average price of $25.0193 per share.
After this sale, Wythburn Associates held 3,000 shares of Precipio common stock. Separate entries show Sandberg with 25,000 shares held indirectly through a Roth IRA and 8,142 shares held directly in his own name. The filing states that Sandberg disclaims beneficial ownership of Wythburn’s securities except to the extent of his pecuniary interest.
Precipio, Inc. director Richard A. Sandberg reported net open-market sales of 3,134 shares of common stock. On May 19–20, 2026, he sold 2,034 shares held directly at prices around $24.89 per share, leaving 8,142 directly owned shares.
Additional sales of 600 and 500 shares were made by Wythburn Associates, Ltd, an entity 94% owned jointly by Sandberg and his spouse, at weighted average prices near $24.42 and $25.00. Sandberg disclaims beneficial ownership of these Wythburn shares except for his pecuniary interest. After these transactions, Wythburn held 3,900 shares, and a Roth IRA for Sandberg’s benefit held 25,000 shares.
PRPO submitted Form 144 reporting proposed or completed sales of Common Stock by holders. The filing lists open-market dispositions of 500 shares (05/22/2025), 101 shares (05/27/2025), and 1,399 shares (05/30/2025) with corresponding sale dates in late May–June 2025. It also shows 2,034 shares issued as equity compensation on 04/15/2024.